About exicure inc - XCUR
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.
XCUR At a Glance
Exicure, Inc.
400 Seaport Court
Redwood City, California 94063
| Phone | 1-847-673-1700 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -4,946,000.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
XCUR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.799 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.165 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.006 |
XCUR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -618,250.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
XCUR Liquidity
| Current Ratio | 1.189 |
| Quick Ratio | 1.189 |
| Cash Ratio | 0.963 |
XCUR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -33.077 |
| Return on Equity | -92.466 |
| Return on Total Capital | -120.575 |
| Return on Invested Capital | -62.171 |
XCUR Capital Structure
| Total Debt to Total Equity | 4.483 |
| Total Debt to Total Capital | 4.291 |
| Total Debt to Total Assets | 1.185 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |